

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

ANTISENSE PROPERTIES OF 2'-O-DIMETHYLAMINOXYETHYL (2'-O-DMAOE) OLIGONUCLEOTIDES

Thazha P. Prakash^a; Andrew M. Kawasaki^a; Joseph F. Johnston^a; Mark J. Graham^a; Thomas P. Condon^a; Muthiah Manoharan^a

^a Isis Pharmaceuticals, Carlsbad, California, U.S.A.

Online publication date: 31 March 2001

To cite this Article Prakash, Thazha P. , Kawasaki, Andrew M. , Johnston, Joseph F. , Graham, Mark J. , Condon, Thomas P. and Manoharan, Muthiah(2001) 'ANTISENSE PROPERTIES OF 2'-O-DIMETHYLAMINOXYETHYL (2'-O-DMAOE) OLIGONUCLEOTIDES', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 829 — 832

To link to this Article: DOI: 10.1081/NCN-100002439

URL: <http://dx.doi.org/10.1081/NCN-100002439>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ANTISENSE PROPERTIES OF 2'-O-DIMETHYLAMINOXYETHYL (2'-O-DMAOE) OLIGONUCLEOTIDES

Thazha P. Prakash,* Andrew M. Kawasaki, Joseph F. Johnston,
Mark J. Graham, Thomas P. Condon, and Muthiah Manoharan

Isis Pharmaceuticals, 2292 Faraday Ave., Carlsbad, California 92008

ABSTRACT

Antisense oligonucleotides with 2'-O-{2-[N,N-dimethyl]aminoxy}ethyl} or (2'-O-DMAOE) modification were synthesized and evaluated for nuclease resistance and pharmacology both *in vitro* and *in vivo*. This modification exhibits very high nuclease resistance and efficacy in various biological (ICAM-1, C-raf and PKC- α) targets.

Antisense oligonucleotides are chemically modified in order to increase the binding affinity to target RNA, to enhance the nuclease resistance, to improve cellular absorption and/or modulate the protein binding of oligonucleotides (1). A number of modifications at 2'-position of the sugar have successfully met one or more of these goals (2). 2'-O-Dimethylaminoxyethyl (2'-O-DMOE) (Fig. 1) is a new carbohydrate modification which exhibits high binding affinity towards target RNA and high nuclease resistance in a snake venom phosphodiesterase assay (3). Here we report the *in vivo* nuclease resistance, *in vitro* and *in vivo* pharmacology of 2'-O-DMAOE antisense oligonucleotides.

We synthesized (4) 2'-O-DMAOE phosphoramidites of all four nucleosides (A, T, C, G) with standard protecting groups for the exocyclic amino groups (Fig. 2). The modified nucleosides were also converted into their 3'-O-succinyl derivative and loaded on to amino alkyl controlled pore glass (CPG Fig. 2) using a standard

*Corresponding author.




Figure 1.

synthetic procedure (5) to get functionalized solid supports in 55–60 $\mu\text{mol/g}$ loading capacity. Modified oligonucleotides were synthesized with these building blocks.

Gapmer phosphorothioate oligonucleotides with five 2'-O-DMAOE modifications on 3' and 5' wings were synthesized for evaluation of *in vivo* stability (Table 1). A full phosphorothioate oligonucleotide **1**, a mixed backbone oligonucleotide **2** with phosphodiester at the wings, phosphorothioate at the gap were administered to BalbC mice by IP injection at a 50 mg/kg dose. After 24 h mice were sacrificed and the oligonucleotides were isolated from liver, kidney and spleen. The percentage of full length oligonucleotides in each organ was determined by CGE analysis. After 24 h almost 100% full length phosphorothioate oligonucleotide **1** was isolated from these organs whereas only 25–40% of mixed backbone oligonucleotide **2** was isolated.

Two fully modified oligonucleotides (**3** and **4**, Table 2) with 2'-O-DMAOE modifications targeted to the ICAM-1 mRNA (6) were analyzed for inhibition




Figure 2. 2'-O-DMAOE nucleoside phosphoramidite building blocks and functionalized CPGs.



Table 1. 2'-O-DMAOE Oligonucleotides Used for Evaluation of *In Vivo* Stability

No.	Sequence	ES MS	
		Calcd	Found
1	5'A*sT*sG*sC*sA*sTsTsC†sTsGsC†sC†sC†sC†sA*sA*sG* sG*sA* 3'	7494.7	7496.3
2	5'A*oT*oG*oC*oA*sTsTsC†sTsGsC†sC†sC†sC†sA*oA*oG *oG*oA* 3'	7368.1	7367.9

A* = 2'-O-DMAOE A, C* = 2'-O-DMAOE ^{5Me}C, G* = 2'-O-DMAOEG,
T* = 2'-O-DMAOE ^{5Me}U, s = PS, o = PO, C† = ^{5Me}C.

of IL-1 β stimulated ICAM-1 protein expression in HUVEC cells. These antisense oligonucleotides efficiently reduced the expression of ICAM-1 protein by a non-RNase H mediated antisense mechanism with an IC₅₀ of 2 nM. These results demonstrate the high binding affinity of 2'-O-DMAOE modified oligonucleotides to the target mRNA. In another cell-based experiment gapmer oligonucleotide **5** reduced the expression of PKC- α mRNA (7) in human A549 cells with an IC₅₀ of 50 nM. This oligonucleotide causes mRNA cleavage by recruitment of RNase H.

We have also examined the efficiency of 2'-O-DMAOE modified oligonucleotide to modulate *in vivo* mRNA expression by RNase H mediated antisense mechanism. Gapmer oligonucleotides (**6** and **7**) with 2'-O-DMAOE modifications in the wings were synthesized to target *C-raf* mRNA. Female BALB/C mice were administered oligonucleotides at 3, 10, 25 and 50 mg/kg, once daily for three days. The mice were sacrificed and the tissue was harvested for analysis. Total mRNA was isolated. Quantitation (8) of the mRNA was done by Northern Blot and PhosphorImager analysis. Oligonucleotide **6** was a very potent inhibitor of the C-raf

Table 2. 2'-O-DMAOE antisense Oligonucleotides Used for Pharmacology

No.	Sequence	Target	ES MS	
			Calcd	Found
3	5' T*sC*sT*sG*sA*sG*sT*sA*sG*sC*sA*sG* sA*sG*sG*sA*sG*sC*sT*sC* 3'	ICAM-1	8605.9	8605.5
4	5' T*oC*oT*oG*oA*oG*oT*oA*oG*oC*oA* oG*oA*oG*oG*oA*oG*oC*oT*oC*3'	ICAM-1	8300.6	8300.5
5	5'T*sT*sC*sT*sC*sGsC†sTsGsGsTsGsAsGsT* sT*sT*sC*sA [▲] 3'	PKC- α	7146.4	7146.4
6	5'A*sT*sG*sC*sA*sTsTsC†sTsGsC†sC†sC†sC† sC†sA*sA*sG*sG*sA* 3'	C-raf	7496.1	7496.1
7	5'A*oT*oG*oC*oA*sTsTsC†sTsGsC†sC†sC† sC†sA*oA*oG*oG*oA* 3'	C-raf	7368.1	7367.9

A* = 2'-O-DMAOE A, C* = 2'-O-DMAOE ^{5Me}C, G* = 2'-O-DMAOEG,
T* = 2'-O-DMAOE ^{5Me}U, A[▲] = 2'-O-MOE A, s = PS, o = PO, C† = ^{5Me}C.



mRNA expression. However mixed backbone oligonucleotide **7** was less effective in reducing the mRNA levels.

REFERENCES

1. (a) Cook P. D. in *Antisense Medicinal Chemistry*; Crooke, S. T. Ed. Antisense Research and Application, Vol. 131, Springer-verlag, New York, **1998**, pp. 51–101. (b) Cook, P. D. *Nucleosides & Nucleotides* **1999**, *18*, 1141–1162. (c) Prakash, T. P., Manoharan, M., Fraser, A. S., Kawasaki, A. M., Lesnik, E. A., Owens, S. R. *Tetrahedron Lett.* **2000**, *41*, 4855–4859, and references cited.
2. Manoharan, M. *Biochim. Biophys. Acta* **1999**, *1489*, 117–130. (b) Monia, B. P.; Lesnik, E. A.; Gonzalez, C.; Lima, W. F.; Guinosso, C. J.; Kawasaki, A. M.; Cook, P. D.; Freier, S. M. *J. Biol. Chem.* **1993**, *268*, 14514–14522
3. Prakash, T. P., Kawasaki, A. M., Vasquez, G., Fraser, A. S., Casper, M. D., Cook, P. D., and Manoharan, M. *Nucleosides Nucleotides* **1999**, *18*, 1381–1382.
4. Prakash, T. P.; Kawasaki, A. M.; Fraser, Vasquez, G, Manoharan, M (Communicated).
5. a) Kumar, P.; Sharma, A. K.; Sharma, P.; Garg, B. S.; Gupta, K. C. *Nucleosides and Nucleotides* **1996**, *15*, 879–888. b) TBTU mediated synthesis of functionalized CPG synthesis: Bayer, E.; Bleicher, K.; Maier, M. A; *Z. Naturforsch.* **1995**, *50b*, 1096–1100.
6. (a) Baker, B., F.; Lot, S.; Condon, T. P.; Cheng-Flourong, S.; Lesnik, E. A.; Sasmor, H. m.; Bennett, F. C. *J. Biol. Chem* **1997**, *272*, 11994–12000. (b) Bennett, C. F.; Condon, T. P.; Grimm, S.; Chan, H.; Chiang, M. Y. *J. Immunol.* **1994**, *152*, 3530–3540.
7. Altmann, K. H.; Martin, P.; Dean, N. M.; Monia, B. P. *Nucleosides & Nucleotides* **1997**, *16*, 917–926
8. Cioffi, C. L.; Garay, M.; Johnston, J. F.; McGraw, K.; Boggs, R. T.; Hreniuk, D.; Monia, B. P. *Mol. Pharmacol.* **1997**, *51*, 383–389.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002439>